At a glance
- Originator Bristol-Myers Squibb; University of Wisconsin at Milwaukee
- Developer Bristol-Myers Squibb
- Class Anxiolytics
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 26 Apr 2002 Preclinical trials in Anxiety disorders in USA (unspecified route)